A study to characterize the Pharmacokinetics, Pharmacodynamics, and Safety of anifrolumab in adult type I Interferon test high Systemic Lupus Erythematosus subject with active skin manifestations

Trial Identifier: D3461C00008
Sponsor: AstraZeneca
NCTID:: NCT02962960
Start Date: February 2017
Primary Completion Date: January 2018
Study Completion Date: December 2018
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Hungarian Translation
Korean Translation
Polish Translation
Spanish Translation

Trial Locations

Country Location
Hungary Budapest, Hungary, 1085
Hungary Debrecen, Hungary, 4032
Hungary Zalaegerszeg, Hungary, 8900
Poland Bydgoszcz, Poland, 85-168
Poland Kraków, Poland, 31-011
Poland Warszawa, Poland, 00-874
South Korea Anyang-si, South Korea, 14068
South Korea Busan, South Korea, 49241
South Korea Daegu, South Korea, 41944
South Korea Gwangju, South Korea, 61469
South Korea Incheon, South Korea, 22332
United States of America, CA Palm Desert, CA, United States of America, 92260
United States of America, CA Thousand Oaks, CA, United States of America, 91360
United States of America, FL Orlando, FL, United States of America, 32810
United States of America, NC Charlotte, NC, United States of America, 28204
United States of America, NY New York, NY, United States of America, 10019
United States of America, TN Memphis, TN, United States of America, 38119
United States of America, TX Houston, TX, United States of America, 77034